Case Report Open Access
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2021; 9(11): 2627-2633
Published online Apr 16, 2021. doi: 10.12998/wjcc.v9.i11.2627
Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report
Xu-Yan Hu, Yu-Cheng Fei, Wen-Chao Zhou, Jin-Miao Zhu, Dong-Lai Lv
Xu-Yan Hu, Department of Clinical Medicine, Bengbu Medical College, Bengbu 233030, Anhui Province, China
Yu-Cheng Fei, Dong-Lai Lv, Department of Clinical Oncology, 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei 230031, Anhui Province, China
Wen-Chao Zhou, Intelligent Pathology Institute, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, Anhui Province, China
Jin-Miao Zhu, Department of Pharmaceutical Engineering, Hefei Normal University, Hefei 230601, Anhui Province, China
ORCID number: Xu-Yan Hu (0000-0002-7651-4492); Yu-Cheng Fei (0000-0001-7137-5625); Wen-Chao Zhou (0000-0001-5841-3842); Jin-Miao Zhu (0000-0001-7281-989X); Dong-Lai Lv (0000-0003-4128-6853).
Author contributions: Hu XY and Fei YC were major contributors to the writing of the manuscript; Zhou WC revised the manuscript; Zhu JM interpreted the pharmacological findings; Lv DL treated the patient; all authors approved the manuscript; Hu XY and Fei YC are co-first authors.
Supported by The Natural Science Foundation Project of Anhui Province, No. 1808085MH267; and Key Research and Development Project of Anhui Province, No. 202004a07020020.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong-Lai Lv, BPhty, DVSc, MD, Chief Doctor, Department of Clinical Oncology, 901 Hospital of Joint Logistic Support Force, No. 424 West Changjiang Road, Shushan District, Hefei 230031, Anhui Province, China. lvxunhuan@163.com
Received: December 7, 2020
Peer-review started: December 7, 2020
First decision: December 30, 2020
Revised: January 11, 2021
Accepted: January 27, 2021
Article in press: January 27, 2021
Published online: April 16, 2021

Abstract
BACKGROUND

Osimertinib is the recommended first-line treatment for adult patients with epidermal growth factor receptor (EGFR) mutation positive advanced or metastatic non-small cell lung cancer (NSCLC). However, primary or acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) seems inevitable, and when drug-resistance occurs during treatment with osimertinib, the standard of care is to discontinue the TKI.

CASE SUMMARY

A 57-year-old female patient with lung adenocarcinoma presented with an irritating cough accompanied by chest distress of one month duration. An enhanced head magnetic resonance imaging scan showed brain metastases. An EGFR mutation (exon 21 L858R) was detected in pleural fluid. The patient was treated with oral osimertinib (80 mg once daily) from January 2018 but developed progressive disease on December 2018. She was then successfully treated with re-challenge and tri-challenge with osimertinib (80 mg once daily) by resensitization chemotherapy twice after the occurrence of drug-resistance to osimertinib, and to date has survived for 31 mo.

CONCLUSION

This case may provide some selective therapeutic options for NSCLC patients with acquired drug-resistance who were previously controlled on osimertinib treatment.

Key Words: Osimertinib, Retreatment, Epidermal growth factor receptor, Tyrosine kinase inhibitor, Non-small cell lung cancer, Case report

Core Tip: Osimertinib is the first-line recommended treatment for adult patients with epidermal growth factor receptor mutation positive advanced or metastatic non-small cell lung cancer. Once drug-resistance occurs in osimertinib, the standard of care is to discontinue the tyrosine kinase inhibitor. To the best of our knowledge, this is the first report of successful re-challenge and tri-challenge with osimertinib administered via multiple re-sensitization chemotherapy protocols. This case provides a useful reference for prolonging the efficacy of osimertinib.



INTRODUCTION

With well-established beneficial outcomes in clinical trials, osimertinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which is selective for both EGFR sensitizing mutations and T790M resistance mutations, has been approved as the standard regimen for patients with non-small cell lung cancer (NSCLC) harboring sensitive EGFR mutations[1]. However, acquired resistance to osimertinib has greatly limited its clinical application, which is a challenging problem with only a few proposed solutions. EGFR-TKI retreatment may be an option to overcome first-generation drug resistance, which has not been tested with osimertinib. Here, we report a patient with lung adenocarcinoma and brain metastasis, who was successfully treated by re-challenge and tri-challenge with osimertinib through multiple sensitization chemotherapy protocols after the occurrence of drug resistance to osimertinib. To date, the patient has survived for 31 mo. These findings may provide some selective therapeutic options for NSCLC patients with acquired drug-resistance who were previously controlled with osimertinib.

CASE PRESENTATION
Chief complaints

A 57-year-old woman presented to the outpatient department of our hospital complaining of an irritating cough accompanied by chest distress on December 23, 2017.

History of present illness

In November 2017, the patient developed an irritating cough without obvious inducement, progressive chest tightness and shortness of breath with loss of body weight, no fever and no obvious headache.

History of past illness

Her past medical history was unremarkable.

Personal and family history

No specific personal or family history of disease was recorded.

Physical examination

Her mental state was not good. Superficial lymph nodes were not affected, heart auscultation was normal, but breath sounds disappeared in the right lower lung. Liver and spleen were not enlarged and edema in the lower limbs was not observed.

Laboratory examinations

Routine blood examination, liver and kidney function and electrolyte test indicators were normal. The levels of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) were 143.02 ng/mL (reference value < 5 ng/mL) and 363.77 U/mL (reference value < 40 U/mL), respectively. Blood gases were normal.

Imaging examinations

A chest computed tomography (CT) scan showed irregular high-density lesions in the upper lobe and middle lobe of the right lung, along with multiple enlarged lymph nodes in the mediastinum and effusion in the right thorax. The boundary of the largest lesion, which measured about 37.2 mm × 17.8 mm, was not clear (Figure 1A). Furthermore, an enhanced head magnetic resonance imaging scan showed a metastatic neoplasm on the right parietal lobe of the brain (Figure 1B).

Figure 1
Figure 1 Chest computed tomography scan and brain magnetic resonance imaging from December 2017 to May 2018 . A: Chest computed tomography (CT) scan as baseline before beginning therapy in December 2017; B: Brain magnetic resonance imaging showed a metastatic neoplasm in December 2017; C: Chest CT scan after 2 mo of therapy in March 2018; D: The neoplasm had disappeared in May 2018.
Further diagnostic work-up

Her right thorax was punctured, and approximately 500 mL of pale-yellow pleural fluid was drained. On December 28, 2017, liquid-based thin layer cytology of pleural fluid found abnormal cells consistent with adenocarcinoma. The patient refused a needle puncture biopsy. Proof-of-principle studies have demonstrated the translational potential of circulating tumor DNA (ctDNA) for molecular profiling[2], thus gene analysis using the amplification refractory mutation system (ARMS) method was performed and an EGFR L858R mutation was found in pleural fluid.

FINAL DIAGNOSIS

The patient was diagnosed with lung adenocarcinoma and multiple lymph nodes, pleura and brain metastases. According to the 8th edition of the tumor, node and metastasis classification of lung cancer, the patient was classified as having cT4N2M1b, Stage IVA.

TREATMENT

Osimertinib (80 mg once daily) was started at the beginning of January 2018, as first-line therapy due to the presence of brain metastasis. During treatment, reexamination of serum tumor markers and a further CT scan showed reduced foci (Figure 1C), and decreased CA199 and CEA levels, which suggested that the treatment was effective. After 5 mo of treatment, the brain metastatic lesion disappeared (Figure 1D) and multiple foci in the lung were reduced, indicating the clinical benefit of osimertinib. At that time, there were no new neoplasms in the right pleura (Figure 2A). However, in December 2018, a lung CT scan showed multiple new foci in the right pleura, indicating further progressive disease (PD) (Figure 2B). A plasma ctDNA analysis using the ARMS polymerase chain reaction (PCR) method was performed and the result showed that the EGFR mutation had disappeared. Osimertinib was then discontinued, and three cycles of pemetrexed plus cisplatin chemotherapy were administered. In March 2019, the primary foci were stable, but the pleural metastatic lesions had enlarged and increased slightly (Figure 2C). A second plasma ctDNA analysis using the ARMS PCR method was carried out and showed the emergence of the EGFR L858R mutation again. Therefore, a second administration of osimertinib was prescribed as third-line therapy (re-challenge). After 2 mo of administration, the pleura foci almost disappeared (Figure 2D), indicating the success of re-sensitization chemotherapy and the effectiveness of osimertinib. In September 2019, the pleural metastatic lesions began to enlarge again (Figure 2E), suggesting the reappearance of drug resistance to osimertinib. The patient refused further gene detection. As a result, osimertinib was again discontinued, and two cycles of chemotherapy with albumin-bound paclitaxel plus cisplatin once every 3 wk was administered instead. However, although the primary lesion remained stable, new lesions continued to appear on the right pleura (Figure 2F). Osimertinib (80 mg once daily) was given for the third time (tri-challenge) as fifth-line therapy on October 14, 2019. After 40 d, regular chest CT scanning showed that the pleural lesions had disappeared again (Figure 2G and H), the primary foci were stable, and the metastatic brain lesion did not recur.

Figure 2
Figure 2 Chest computed tomography scans from October 2018 to November 2019 . A: Baseline image of the right pleura in October 2018; B: New foci in the pleura showed progressive disease in December 2018; C: The pleural metastatic lesions enlarged and increased in March 2019; D: The pleura foci almost disappeared after 2 mo of retreatment with osimertinib in May 2019; E and F: Secondary enlargement and increase of metastatic pleural foci in September and October 2019; G and H: The neoplasms disappeared again after 40 d tri-challenge with osimertinib in December 2019.
OUTCOME AND FOLLOW-UP

Treatment outcome suggested that multiple osimertinib administrations followed by chemotherapy in this patient with advanced lung adenocarcinoma and acquired resistance improved survival. The patient feels good, has no symptoms and is still currently receiving osimertinib treatment. To date, overall survival (OS) in this patient is 31 mo. The entire treatment course with fluctuations in CEA is shown in Figure 3.

Figure 3
Figure 3 Entire treatment course with variations in carcinoembryonic antigen levels at each visit from the initial treatment to the present. EGFR: Epidermal growth factor receptor; CEA: Carcinoembryonic antigen.
DISCUSSION

EGFR-TKI has become the standard treatment choice for NSCLC patients with EGFR sensitive mutations, and the emergence of the third-generation EGFR-TKI, osimertinib, has effectively prolonged progression-free survival (PFS) in NSCLC patients[3]. However, EGFR-TKI drug resistance is difficult to avoid. Therefore, clinical oncologists are facing a challenge to effectively overcome drug resistance to osimertinib. Some retrospective studies[4-7] and a prospective study with a small cohort[8] noted that EGFR-TKIs could regain effectiveness when applied after one or several cycles of chemotherapy and following the appearance of drug resistance in the treatment of advanced NSCLC. The interval between the use of EGFR-TKIs is also called a “drug holiday” by some scholars. In these studies, erlotinib benefited the survival of some NSCLC patients who had received second-line chemotherapy after progression post-gefitinib treatment. The re-challenge with erlotinib extended the median OS (mOS) after treatment to 14.6 mo, and the patients who had achieved a partial response with previous gefitinib treatment benefited more[9]. In addition, in a retrospective study involving a large cohort, following the occurrence of drug resistance after the administration of first- or second-generation EGFR-TKIs (gefitinib, erlotinib and afatinib), NSCLC patients with EGFR mutations received re-sensitization chemotherapy and were then retreated with these EGFR-TKIs. In that study, the objective response rate (ORR) and disease control rate (DCR) were 7.3% and 44.4%, respectively, and median PFS (mPFS) and mOS were 4.1 and 12.6 mo, respectively. Moreover, in the subgroup analysis, the patients with an interval of ≥ 7 mo between two targeted treatments and female patients with an exon21 mutation were found to be the dominant populations responding to re-challenge treatment[7]. In the latest multicenter, prospective phase II study, following the failure of first-line treatment with gefitinib, at least four cycles of dual drug chemotherapy with platinum were given and then third-line treatment with gefitinib was administered again. It was found that the predefined DCR was achieved in 69.8% of patients and an ORR was observed in 4.7% of patients. mPFS was 4.4 mo and mOS was 10.3 mo. Baseline T790M-negative patients achieved a favorable DCR, mPFS and mOS compared with T790M-positive patients[8]. All the above studies strongly suggest that re-challenge with EGFR-TKIs should be included as an important part of the whole management process for EGFR mutation positive NSCLC patients.

However, up to now, no NSCLC patients showing drug resistance after the application of osimertinib who were given re-sensitization chemotherapy and benefited from this treatment have been reported. To our knowledge, this is the first report of this successful treatment regimen. At present, osimertinib is the recommended first-line drug for NSCLC patients with EGFR mutations. In addition, preclinical studies have shown that osimertinib was more effective than first- or second-generation EGFR-TKIs in treating brain metastases and meningeal carcinomatosis in EGFR mutation positive NSCLC patients[10]. Clinically, osimertinib demonstrated remarkable efficacy against central nervous system metastases in a pooled analysis of two phase II studies of osimertinib for T790M-positive NSCLC[11]. Thus, in our patient, following the identification of brain metastases, osimertinib was prescribed as first-line therapy and successfully eradicated the brain metastases. Then, after the first occurrence of drug-resistance to osimertinib treatment and the progression of pleural foci, the first re-sensitization with osimertinib was successful. When drug-resistance to osimertinib treatment occurred again and pleural foci progressed for the second time, the administration of osimertinib was again discontinued, and the second re-sensitization therapy was carried out via two cycles of chemotherapy. Subsequently, osimertinib was administered for a third time, and the tri-challenge succeeded once again. This multiple re-sensitization treatment protocol has allowed this patient with stage IVA lung cancer to survive for 31 mo with a good quality of life, and only mild side effects during the entire treatment process.

Several models have been used to explain the phenomenon of re-sensitization followed by chemotherapy after EGFR-TKIs resistance. The selection stress model is one of the most convincing models. EGFR mutant cancer cells actively proliferate and have a growth advantage in the heterogeneous tumor cell population before EGFR-TKIs treatment. However, due to their high sensitivity to EGFR-TKIs treatment, most of the EGFR mutant cells will be removed during the first round of EGFR-TKIs treatment, while the few remaining cells with resistance to EGFR-TKI will gradually become the dominant population, leading to the development of EGFR-TKI resistance. On the other hand, chemotherapy does not inhibit tumor growth by suppressing the EGFR pathway, but inhibits cancer cell division by cytotoxicity. At this time, the discontinuation of EGFR-TKIs treatment along with the administration of chemotherapy will have a significant impact on the EGFR-TKI resistant cell population. The sensitivity to EGFR-TKI could then be restored without EGFR-TKI selection stress. Consequently, lung cancer cells will be inhibited by EGFR-TKIs again[12]. This theory has been proved in the targeted treatment of colon cancer, as third-line treatment with repeated cetuximab benefited 54% of the patients with RAS and BRAF wild-type metastatic colorectal cancer who acquired resistance to first-line cetuximab and irinotecan[13]. The results of gene analysis using plasma or pleural fluid samples from our patient also validated this theory. Before the first administration of osimertinib, an EGFR exon21 L858R mutation was present. Then at the first PD after twelve months, the mutation was not found on ctDNA analysis. This may reflect that EGFR mutant cancer cells were no longer the dominant population. However, with discontinuation of osimertinib treatment along with several cycles of chemotherapy, the same mutation appeared again in plasma and osimertinib treatment was successful once more. This may explain why the second osimertinib administration succeeded again. Unfortunately, the patient refused subsequent genetic testing during the third osimertinib treatment, and this prevented us from obtaining more information for a deeper understanding of this phenomenon.

CONCLUSION

In summary, to the best of our knowledge, this is the first report of successful re-challenge and tri-challenge with osimertinib administered via multiple re-sensitization chemotherapy protocols. This case provides a useful reference for retreatment with osimertinib. We also look forward to further multi-center prospective studies with a larger sample size.

Footnotes

Manuscript source: Unsolicited manuscript

Specialty type: Oncology

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Lee S, Wu W S-Editor: Zhang H L-Editor: Webster JR P-Editor: Ma YJ

References
1.  Le T, Gerber DE. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? Cancers (Basel). 2019;11.  [PubMed]  [DOI]
2.  Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223-238.  [PubMed]  [DOI]
3.  Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15:694-708.  [PubMed]  [DOI]
4.  Tomizawa Y, Fujita Y, Tamura A, Shirai M, Shibata S, Kawabata T, Shibayama T, Fukai S, Kawahra M, Saito R. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer. 2010;68:269-272.  [PubMed]  [DOI]
5.  Oh IJ, Ban HJ, Kim KS, Kim YC. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer. 2012;77:121-127.  [PubMed]  [DOI]
6.  Xia GH, Zeng Y, Fang Y, Yu SR, Wang L, Shi MQ, Sun WL, Huang XE, Chen J, Feng JF. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI. Cancer Biol Med. 2014;11:270-276.  [PubMed]  [DOI]
7.  Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study. Lung Cancer. 2017;104:58-64.  [PubMed]  [DOI]
8.  Song Y, Wu YL, Cao LJ, Chen JH, Ma ZY, Cui JW, Wang J, Liu HB, Ding JY, Hu M. Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304). Am J Clin Oncol. 2019;42:432-439.  [PubMed]  [DOI]
9.  Vasile E, Tibaldi C, Chella A, Falcone A. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J Thorac Oncol. 2008;3:912-914.  [PubMed]  [DOI]
10.  Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016;22:5130-5140.  [PubMed]  [DOI]
11.  Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018;29:687-693.  [PubMed]  [DOI]
12.  Becker A, Crombag L, Heideman DA, Thunnissen FB, van Wijk AW, Postmus PE, Smit EF. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer. 2011;47:2603-2606.  [PubMed]  [DOI]
13.  Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2019;5:343-350.  [PubMed]  [DOI]